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Matthias Edinger,1 Fiona Powrie,2 Ronjon Chakraverty3Graft-versus-host disease (GVHD) is induced by donor T cells cotransplanted with the stem cell graft. The
main risk factors for the development of GVHD are the degree of HLA disparity between donor and recipient
and the precursor frequency and intensity of T cell responses against major or minor histocompatibility an-
tigens. However, allogeneic T cell responses do not occur in a static and sterile environment, but are modu-
lated by the inflammatory milieu in lymphoid and GVHD target tissues that influences the functional
characteristics of antigen presenting cells APCs. Here, we summarize our recent findings concerning the
pro- and anti-inflammatory function of (APCs) in the gastrointestinal tract, the role of APCs in the induction
of GVH and graft-versus-leukemia (GVL) responses, and their influence on suppressive effects mediated by
regulatory T cells.
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Graft-versus-host disease (GVHD) is the main
complication after allogeneic stem cell transplantation
(SCT) and induced by donor T cells in the graft. As in
physiological T cell responses, alloreactive T cells de-
pend on their activation by antigen presenting cells
(APCs). Potential APCs are B cells, monocytes/mac-
rophages, and mainly dendritic cells (DC), the most
efficient cells in antigen uptake, processing, and pre-
sentation on HLA class I and class II molecules. In
HLA-mismatched SCT, HLA molecules are recog-
nized directly by donor T cells with a variable contri-
bution of the HLA-bound peptide, whereas minor
histocompatibility antigens (mHA) are the main tar-
gets in HLA-identical SCT. These mHA consist of
HLA-bound peptides derived from polymorphic pro-
teins that differ between donor and recipient. Al-
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6/j.bbmt.2008.10.013almost all cells, class II expression is mainly restricted
to hematopoietic cells. HLA class I molecules primar-
ily present peptides derived from cytosolic proteins
that are processed by the proteasome and loaded
onto HLA I within the endoplasmatic reticulum (en-
dogeneous pathway of Ag processing). Exogenous an-
tigens are more efficiently presented by HLA class II
molecules that are loaded with peptides derived from
phagocytosed antigens within the lysosomes. Those
exogenous and endogenous pathways of antigen pro-
cessing are not mutually exclusive, as especially DCs
have the capacity to also crosspresent exogenous anti-
gens in HLA class I molecules [1]. Thus, DCs that pa-
trol through peripheral organs can collect antigens
from those sites and present the peptides after their
migration to regional lymph nodes to naı¨ve T cells
to prime CD41 and/or CD81 T cell responses.
Whether or not an immune response is initiated de-
pends on the activation status of the APC. In the
steady state, APCs are not activated and do not trigger
inflammatory T cell responses, but rather downregu-
late T cell function [2]. However, APCs express a vari-
ety of pattern recognition receptors (PRRs). Triggering
of PRRs efficiently stimulates APCs, which in turn,
upregulate costimulatory molecules and secret pro-
inflammatory cytokines. Such costimulation in combi-
nation with secreted cytokines provide the ‘‘danger
signals’’ for the initiation of an inflammatory T cell re-
sponse. Activated T cells then upregulate stimulatory
ligands such as CD40L and secrete Th1 cytokines
that further perpetuate the pro-inflammatory capacity
of APCs [3].
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versus-Leukemia (GVL)
Over the last 10 years, a number of groups explored
the role of APCs in the development of GVHD [4,5]
and GVL responses [6,7]. Shlomchik and his collabo-
rators [4] showed that bone marrow chimeras lacking
major histocompatibility complex (MHC) class I ex-
pression on hematopoietic cells are resistant to
GVHD induction after MHC-matched, mHA-mis-
matched transplantation, indicating a requirement
for host APCs. Similarly, host APCs are pivotal for
the induction of potent GVL responses in the early
phase after transplantation [7]. In contrast, donor
APCs appear to be less important, suggesting that
crosspresentation of host antigens by donor-derived
APCs is not required for the induction of severe
GVHD, although it exacerbates GVHD in some
models [8]. However, donor APCs may contribute to
the perpetuation of tissue injury in chronic GVHD
(cGVHD) [9,10] and may promote GVL activity
when the tumor burden is low [7].
In most models, the role of APCs was examined
early after transplantation when the conditioning-
induced tissue injury contributes to inflammation and
pathogen-derived products, such as lipopolysaccha-
rides (LPS), trigger PRRs on regional APCs [11]. To
evaluate the influence of such factors, several groups ex-
plored the biology ofGVHDafter delayed donorT cell
transfer when the conditioning-induced tissue injury
has subsided. The delayed transfer of donor T cells to
mixed allogeneic chimeras maintained GVL responses
but reduced the incidence and severity of GVHD
[12,13]. Over time, however, even GVL activity is lost
in chimeras [14], which might be caused by a decrease
in host APCs, the lack of inflammation, and/or the
evolvement of immunoregulatory cell populations
[15]. In our experiments (R.C.), maximal GVL re-
sponses against an MHC class II-negative tumor after
MHC-mismatched transplantation required expres-
sion of not only class I but also class II MHC by host
APCs [6,16]. In this model, maximal expansion of
host-reactive donorCD81Tcells andGVLactivity de-
pended upon both the presence of CD41T cells within
the donor leukocyte infusion (DLI) and the persistence
of residual host APCs [16]. Thus, donor CD41 T cells
seem to ‘‘license’’ host APCs for the priming of GVH
reactive cytotoxic T lymphocyte (CTL) responses.
Yet, in sharp contrast to freshly conditioned hosts, the
antihost CD81 T cell populations expanding in mixed
hematopoietic chimeras demonstrate relative func-
tional defects, including delayed kinetics of differentia-
tion into effector cells, reduced expression of effector
molecules (eg, interferon-gamma [IFN-g]), impaired
cytotoxicity, and higher rates of sustained apoptosis
[17]. Such per-cell deficits could be overcome by trans-
ferring larger numbers of T cells, without increasingthe rate of GVHD, as the alloresponse was largely re-
stricted to the lymphohematopoietic system. The
high frequency and avidity of donor T cell receptors
for host MHC may have contributed to the efficient
priming of host APCs in this model and explain why
GVL activity depended upon MHC alloreactivity,
whereas little or noGVL activity against minorH anti-
gens or tumor-associated antigens (TAA) was detected
[16,18]. Inmodels involvingT cell transfers into freshly
irradiated mice the requirement for shared alloantigen
expression by host APCs and tumor cells has been con-
firmed, although reactivity against mHA was sufficient
to induce GVL in this situation [7,15]. Indeed, even
crosspresentation of alloantigens and/orTAAby donor
APCs may contribute to GVL activity under such pro-
inflammatory conditions [7]. Thus, alloreactive donor
T cells seem to license host DCs for the initiation of
GVL responses in the absence of inflammationwhereas
additional factors such as PRR triggering and the cyto-
kine storm seem to boost GVL and GVHD responses
in recently conditioned lymphopenic animals. In line
with these findings, localized skin GVHD could be
induced after delayed DLI in mixed chimeras if topical
TLR agonists were administered [6]. Similarly, the sys-
temic administration of TLR agonists augmented the
conversion from mixed to full chimeras after delayed
DLI, confirming that the activation status of residual
hostAPCdeterminesDLI-mediated alloreactivity [18].
The long-term success of GVL may depend on
memory-effector cells capable of mounting a recall re-
sponse against residual tumor cells and in many pa-
tients, antitumor responses are poorly sustained
[12,19]. In our model of delayed donor T cell transfer
into mixed chimeras, initial expansion of CD81T cells
bearing a high-affinity T cell receptor (TCR) for host
antigens is followed by partial, but incomplete deletion
[20]. Yet, despite the continued presence of anti-host
CD81 T cells, little recall immunity is established
andmice are susceptible to tumors upon subsequent re-
challenge [20]. The reasons for this are unclear, but it is
known that the initial GVH response eradicates host
APCs, leaving only donor APCs that are less efficient
at eliciting GVL. Although ‘‘add back’’ of host DCs
at the time of donor T cell transfer to full chimeras
can help to induce a primaryGVL response [15], a sim-
ilar strategy fails to rescue a secondary response several
weeks following delayed donor T cell transfusion into
mixed chimeras (R. Chakraverty, unpublished data).
It will be important to determine themechanism(s) un-
derlying this deficit to develop improved DLI strate-
gies that endorse durable GVL activity.
Regulatory T Cell-Mediated
Immunosuppression
Recently, several groups examined the immuno-
suppressive activity of donor CD41CD251 regulatory
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marrow transplant (BMT) models. CD41CD251
Treg cells are thymus-derived suppressor cells that
prevent autoimmunity by inhibiting peripheral prolif-
eration and differentiation of autoreactive T cells that
escaped thymic deletion [21]. Treg cells constitutively
express FOXP3, a transcription factor required for
their thymic generation and peripheral function
[22-24]. Mutations in the FOXP3 gene result in lack
of this Treg cell population and cause lethal
autoimmunity in mice and man (scurfy and IPEX
[immundysregulation, polyendocrinopathy, enteropa-
thy, X-linked], respectively) [25,26]. As Treg cells are
pivotal for immune homeostasis during ontogeny, it
is assumed that they are also crucial for lymphoid
reconstitution after SCT. The main functional charac-
teristics of CD41CD251 Treg cells in vitro are their
hyporesponsiveness to standard T cell stimulation,
their inability to produce proinflammatory cytokines,
and their potent suppression of both CD41CD252
and CD81T cells after their own activation. In murine
models, donor-derived CD41CD251 Treg cells do
not induce GVHD after allogeneic BMT even when
transplanted in high numbers and across complete
MHC barriers. In contrast, donor CD41CD251
Treg cells prevent GVHD induced by nonregulatory
donor T cells when cotransplanted at a 1:1 ratio [27-
29]. Importantly, cotransfer of CD41CD251 Treg
cells neither interfered with stem cell engraftment
[30] nor did it paralyze the T cell compartment, as
GVL activity was maintained [31]. Suppression of
GVHD by donor CD41CD251 Treg cells was
achieved by restricting the early expansion of allo-
reactive conventional T cells in these models [31].
The relevant sites of suppression seemed to be
lymphatic organs, because only CD41CD251 Treg
cells with lymph node homing capacity protected
from lethal GVHD [32,33]. Thus, residual host APC
seem to activate not only effector T cells after alloge-
neic BMT, but also immunosuppressive Treg cells.
The mechanism of Treg-mediated suppression is not
yet fully identified, but seems to involve several path-
ways that not only act on effector T cells, but alsomod-
ulate the function ofDCs such that they down-regulate
their proinflammatory activity [34]. Because Treg cells
gain suppressive activity only after their own activation,
Nguyen and colleagues [35] speculated that the in vivo
preactivation and expansion of alloreactive donor Treg
cells enhances their protective effect. In fact, they
found efficient protection from GVHD after MHC-
mismatched BMT even at physiological Treg to T ef-
fector cell ratios (1:10) if Tregs were administered 2
daysbefore the effector cell population.Whether a sim-
ilar efficiency for GVHD prevention can be achieved
after MHC-matched BMT requires further investiga-
tions, as the precursor frequency of alloreactive Treg
cells is expected to be lower in this setting. Thus far,it has been difficult to unequivocally identify respond-
ing (and thus suppressive) Treg cells after allogeneic
stimulation, as activated Treg cells do not necessarily
secrete cytokines and express several surface activation
markers constitutively. Although Treg cell priming by
DCs in lymphoid organs is pivotal for the protection
from GVHD, they are also recruited to GVHD target
tissues and seem to inhibit target organ damage locally
after their initial activation in regional lymph nodes
[36]. Importantly, the suppressive activity of Treg cells
does not impair but rather improves immune reconsti-
tution in experimental BMT, becauseTreg cells inhibit
the destruction of lymphoid tissues that usually occurs
in acuteGVHD(aGVHD; [37,38] andM.Edinger, un-
published data). In summary, these studies revealed
that the immunosuppressive activity of donor
CD41CD251Treg cells could be exploited to amelio-
rate or prevent alloresponses after BMT without
inducing a complete paralysis of donor T cell function.Immunoregulation in the Gastrointestinal Tract
Main target organs of acute GVHD are the gastro-
intestinal tract (GI), liver, and skin, but severe gut
GVHD is mostly responsible for GVHD lethality in
experimental models and transplanted patients. The
GI tract has a huge surface area that is constantly ex-
posed to an infinite amount of antigens, such as envi-
ronmental antigens, nutrition, commensal flora, and
potential pathogens. Although physicochemical bar-
riers (epithelial membrane, mucus, pH, defensins, se-
creted IgA, etc.) represent the most important
barriers for the prevention of pathogen invasion, the
GI tract is also constantly patrolled by cells of the in-
nate immune system and hosts the largest lymphoid
tissue in the body. The mucosa contains specialized
DCs that sense external stimuli and orchestrate the im-
mune response depending on the encountered ele-
ments [39]. Considering the huge amount and variety
of intraluminal antigens, the primary function of those
cells under steady-state conditions is either to ignore
or to actively prevent immune responses to harmless
antigens [40]. Interestingly, FOXP31 Treg cells
seem to be involved in themaintenance of immune tol-
erance within the GI tract, as scurfymice and IPEX pa-
tients develop severe GI inflammation and unusual
immune responses, for example, severe food allergies.
Furthermore, natural Treg cells efficiently protect
mice from chemically (DSS) or immunologically in-
duced colitis upon adoptive transfer [41], and colitis
is one of the rare disease models, where Treg cells
cure established disease [42]. However, immune ho-
meostasis within the GI tract is not solely controlled
by thymus-derived natural Treg cells, but also by the
peripheral induction of Foxp3 expression in naı¨ve T
cells. Specialized DCs expressing the integrin CD103
are enriched in the colon and mesenteric lymph nodes
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an antigen-specific manner [43,44]. The induction of
Foxp3 depends on tumor growth factor-beta (TGF-
b) and the vitamin A metabolite, retinoic acid. Al-
though the molecular mechanisms involved in the
induction of Treg cells are not yet characterized in de-
tail, these new discoveries suggest that T cell-mediated
suppression can evolve in peripheral organs to prevent
deleterious immune responses toward external anti-
gens. As many external but harmless antigens are not
expressed in the thymus during T cell development,
such peripheral mechanisms might maintain local
immune tolerance. Interestingly, CD1031 DCs not
only induce Foxp3 expression, but also imprint gut
homing receptor expression on induced Treg cells
[45]. Thus, tissue-specific tolerance mechanisms that
involve close interactions of specialized APC with T
cell subpopulations contribute to self-tolerance and
the organ tropism of aGVHD suggests that alterations
in such mechanismsmight contribute to the pathogen-
esis of GVHD. Of note, GVHD target organs are
either densely populated by DCs (gut and skin)
or the first efferent organ (liver) of gut-invading path-
ogens and their products (PAMPs). Improving our
understanding of physiological tolerance mechanisms
operational in these organs might provide further
insight into GVHD pathophysiology and pave a way
toward improved GVHD prevention strategies.CONCLUSION
Almost all of the findings described above are de-
rived from preclinical models that are purposely de-
signed to reduce many variables that apply in the
human setting. For example, the influence of immuno-
suppressive drugs has not been examined in any of
those studies. Yet, current immunosuppressants do
not specifically act on T cells, but also influence vari-
ous other hematopoietic cells (including APCs) as
well as nonhematopoietic tissues (eg, epithelial and en-
dothelial cells). Because peripheral self-tolerance is not
a passive, but is an active accomplishment of the
immune system even under physiologic conditions,
improved immunosuppressive therapies should aim
at the preservation of tolerance-promoting mecha-
nisms, whereas restricting inflammatory alloresponses.
Clearly, donor T cells are the main players in the in-
duction of GVHD, but instead of their functional inac-
tivation or their complete eradication, it might be
preferable to modulate their environment such that al-
logeneic responses are restricted to lymphohemato-
poietic tissues, the most sensitive target of donor T
cells. As the pathogenesis of GVHD is multifactorial,
such alternative GVHD prevention strategies could
(and partially do) aim for minimization of the
conditioning toxicity (protection of endothelial andepithelial cells), the prevention of PRR triggering on
APCs, the modulation of T cell migration, and the
conservation of APC- and T cell-mediated immuno-
regulation.ACKNOWLEDGMENTS
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